Ensures a full course of therapy in one, affordable injection, alleviating oral treatment compliance concerns

Dechra, the global leader in veterinary specialty care, is proud to announce the U.S. launch of Solovecin™ (cefovecin sodium), a long-acting injectable antibiotic for the treatment of skin infections in dogs and cats — the top reason veterinarians prescribe antibiotics.¹ With skin infections affecting 10-15% of the canine population and up to 20% of the feline population, Solovecin gives veterinarians an affordable tool to extend quality care to more patients, including cats and larger dogs.^2,3,4

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103668371/en/

Dechra announces U.S. launch of Solovecin™ (cefovecin sodium), an in-clinic antibiotic solution for skin infections in dogs and cats.

Solovecin is now available for order from all major veterinary distributors.

Poor compliance leads to more than just poor outcomes

Compliance with medication administration isn’t just a challenge; it’s a risk. Inconsistent antibiotic administration contributes to treatment failure, more expense and time at the veterinary clinic, diminished trust in care, and ultimately, degradation of the special bond people share with their pets.

“When it comes to antibiotics, successful treatment is highly dependent on the drug being given correctly by the pet owner. Missed dosages, abbreviated treatment courses, and inaccurate reporting by the pet owner are common roadblocks," said Darin Dell, DVM, DACVD. "With Solovecin, the patient is getting their full course of treatment in one simple injection at the veterinary clinic, eliminating compliance concerns and supporting better health outcomes."

A smart, practical portfolio for real-world challenges

Skin conditions consistently rank as one of the top reasons for veterinary visits. Dechra’s comprehensive antibiotic portfolio for dogs and cats gives veterinarians the freedom and flexibility to find the right solution for their patients’ needs.

“Solovecin is an exciting addition to our growing antibiotic portfolio and, more importantly, showcases Dechra’s ongoing commitment to providing pragmatic solutions to veterinary healthcare teams,” said Laura Olsen, President, North America and Chief Marketing Officer, Dechra. “Solovecin reflects Dechra’s commitment to preserving the power of the human-animal bond and supporting veterinarians with in-clinic solutions.”

In addition to Solovecin, Dechra’s portfolio includes:

• Clavacillin^® (amoxicillin and clavulanate potassium tablets), USP Veterinary Tablets
• Clavacillin^® (amoxicillin and clavulanate potassium for oral suspension), USP Drops
• Cefpoderm^® (cefpodoxime proxetil tablets)
• Marboquin^® Chewable Tablets (marbofloxacin)
• Enroquin^® (enrofloxacin) Flavored Tablets
• Enroquin^® (enrofloxacin) Antibacterial Injectable Solution 2.27%

About Solovecin

Cefovecin sodium is a semi-synthetic broad-spectrum antibacterial agent from the cephalosporin class. Each mL of Solovecin reconstituted lyophile contains cefovecin sodium equivalent to 80.0 mg cefovecin, methylparaben 1.8 mg (preservative), propylparaben 0.2 mg (preservative), sodium citrate dihydrate 5.8 mg, and citric acid monohydrate 0.1 mg, sodium hydroxide or hydrochloric acid as required to adjust pH.

Dogs:

Solovecin is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Cats:

Solovecin is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.

Important Safety Information

As with all drugs, side effects may occur. People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to Solovecin. Do not use in animals with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia, and lethargy. Refer to the prescribing information for complete details or visit www.dechra-us.com.

To obtain a full Safety Data Sheet, contact Dechra at 1-866-933-2472.

About Dechra

Dechra is a global specialist in veterinary pharmaceuticals and related products. The company focuses on the development, manufacturing, and marketing of high-quality veterinary products to support animal health and welfare worldwide. For more information, visit www.dechra-us.com.

¹ Granick JL, Beaudoin AL, Nielsen LK, Bollig ER. Measurement of antibiotic use in cats and dogs presenting to US primary care and referral practices provides insights for antimicrobial stewardship. Journal of the American Veterinary Medical Association. 2025 May 1;263(5):640-9.

²Older CE, Rodrigues Hoffmann A, Hoover K, Banovic F. Characterization of cutaneous bacterial microbiota from superficial pyoderma forms in atopic dogs. Pathogens. 2020 Aug 6;9(8):638.

³Yu HW, Vogelnest LJ. Feline superficial pyoderma: a retrospective study of 52 cases (2001–2011). Veterinary dermatology. 2012 Oct;23(5):448-e86.

⁴Market Research Findings. Data on File. 2025

This product is only available in the US at this time. This communication may contain information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration, or usage in the country of your origin.

© 2025, Dechra Veterinary Products LLC., all rights reserved. All trademarks are property of Dechra Pharmaceuticals Limited or its affiliates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251103668371/en/

With skin infections affecting 10-15% of the canine population and up to 20% of the feline population, Solovecin gives veterinarians an affordable tool to extend quality care to more patients, including cats and larger dogs.